Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Eltrombopag (ATC-Code nach WHO: B02BX05)

The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to Section 130a (8) SGB V for medicines containing the active substance Eltrombopag (ATC code according to WHO: B02BX05, excluding the indication - acquired severe aplastic anaemia - unless the pharmaceutical company is the holder of valid patent rights or is authorised to distribute by a patent-maintaining licence). The contract is concluded within the framework of a so-called Open-House model, i.e. a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations are not conducted and there is no (supply) exclusivity. It is pointed out that the quantity to be procured is unknown, as it depends on demand and the development of the number of insured persons, the prescribing behaviour of doctors and the dispensing and stocking behaviour of public pharmacies. Accordingly, minimum procurement quantities are not guaranteed. Interested pharmaceutical companies can download the participation documents from the project room of the German TED portal (DTVP). To do this, an application for access to the project room is first required. After the applicant has been enabled by the contracting entity, the participation documents can then be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents - in particular regarding the content of the discount agreement and the discounts mentioned therein. Any full or partial disclosure or provision of contents of the participation documents to or for third parties requires the prior written consent of the contracting entity. If participation is waived, all documents must be destroyed immediately in a data protection-compliant manner. The documents to be submitted are listed in the documents "Cover Letter" and "Explanation of Contract Terms" stored in the project room. Communication, including the transmission of the participation documents, takes place electronically via the DTVP portal; details can be found in the aforementioned documents. Any contrary information in the contract notice is due to technical reasons and is not binding. Participation applications can be submitted for the first time by 3 September 2026. All further submission deadlines can be found in the annex "Submission Deadlines" stored in the project room. If the deadline for submission falls on a Saturday, Sunday or public holiday throughout the country, the next working day shall take its place. In the event of late receipt, the submitted participation applications will be considered for the next submission deadline. The discount agreement ends, regardless of the date of contract conclusion, at the latest on 30 September 2028. The contracting entity reserves the right to terminate the Open-House procedure prematurely, in particular in the event of the conclusion of exclusive discount agreements; in this case, the discount agreements already concluded end in accordance with the contractual provisions. According to the experience of the contracting entity, exclusive discount agreements generally come into force 8 to 12 months after the publication of the corresponding contract notice in the Supplement to the Official Journal of the European Union.